• Compact RNA-Guided Nucleases in Mammalian Cells

  2026-10-13

  Gorbenko and colleagues report a mammalian-cell directed-evolution strategy that improved the activity of compact Cas12f and TnpB RNA-guided nucleases. The findings support these variants as promising research tools, but they do not establish clinical efficacy, universal activity across loci or cell types, or any direct connection to commercial Cas12a mRNA products.

• BAY 11-7082 and Radiotherapy-Immunotherapy Evidence

  2026-10-13

  A source-grounded overview of BAY 11-7082 as an NF-κB pathway research compound and of a 2025 preclinical study linking radiotherapy plus PD-1/TIGIT blockade to CD8+ T-cell-mediated abscopal effects. The available evidence does not establish that Bay 11-7821 (BAY 11-7082) was used in, or would reproduce, the reported combination-therapy findings.

• PR-619 in Context: What the Evidence Shows

  2026-10-12

  PR-619 is described by APExBIO as a reversible, broad-spectrum deubiquitylating enzymes inhibitor for mechanistic cell research. The supplied JCI study, however, investigated decitabine combined with anti–PD-1 therapy—not PR-619—and therefore does not establish a role for PR-619 in T-cell exhaustion, checkpoint blockade, or tumor control.

• Lithium, Exosomal Wnt10a, and Bone Repair

  2026-10-12

  A source-grounded overview of a 2024 ACS Applied Materials and Interfaces study linking lithium-treated bone mesenchymal stem-cell exosomes with Wnt10a secretion, Rab11a-associated trafficking, beta-catenin signaling, and bone regeneration. The evidence is preclinical and does not establish a role for GW 4869 in the cited work.

• PET Tracking of mRNA Antigen Expression: Limits

  2026-10-11

  A 2025 report describes a PET-based reporter strategy for measuring where and how long an mRNA-encoded antigen is expressed in vivo. The findings support non-invasive, whole-body tracking in female mice and male non-human primates, but they do not establish that reporter-fused antigen expression is equivalent to vaccine efficacy, nor do they provide evidence about any specific lipid excipient such as ALC-0159.

• Nonivamide Research: TRPV1, Inflammation and Cancer

  2026-10-10

  A source-grounded overview of Nonivamide as a Capsaicin analog, examining TRPV1 signaling, the 2025 neuroimmune study, reported cancer-related findings, evidence strength, and important translational limitations.

• Camptothecin, DNA Damage, and Adaptive Evolution

  2026-10-09

  A source-grounded overview of Camptothecin as a topoisomerase I inhibitor, its reported DNA-damage and cell-fate effects, and how these findings compare with new evidence on prion-regulated mutagenesis and drug resistance.

• Ibotenic Acid Toxicity in Mice: Dose and Time

  2026-10-09

  A 2026 study in Toxin Reviews provides a structured in vivo assessment of ibotenic acid toxicity in mice across dose and observation time. Its findings connect behavioral changes, transient biochemical disruption, early c-fos activation, and reduced Nissl bodies, while also showing why these markers should not be interpreted as direct evidence of human neurodegenerative disease.

• Amikacin Sulfate: From MIC to Granuloma

  2026-10-08

  Explore how Amikacin Sulfate acts as an aminoglycoside antibiotic and why granuloma-directed delivery could reshape research on non-tuberculous mycobacterial infections. This evidence-focused analysis separates established mechanism, mouse-model findings, and translational limitations.

• GDC-0941: Research Context and Evidence Boundaries

  2026-10-08

  A source-grounded overview of GDC-0941 as a PI3K inhibitor, covering its reported biochemical profile, conceptual oncology applications, evidence provenance, comparison with recent pancreatic cancer research, and limits on interpretation.

• Cinoxacin: From UTI Activity to Evidence Design

  2026-10-07

  Cinoxacin is a quinolone antibiotic with a historically defined Gram-negative activity profile. This article reframes its value for urinary tract infection research, bacterial prostatitis research, and antibiotic resistance studies through evidence design, pharmacology, and applicability limits.

• Difloxacin HCl: An Evidence-Bound Research Map

  2026-10-07

  Difloxacin HCl is a quinolone antimicrobial antibiotic with distinct research applications in bacterial DNA replication inhibition and multidrug resistance reversal. This evidence-bound guide separates established mechanisms from exploratory interpretation and uses mitotic checkpoint research to clarify how mechanistic claims should be evaluated.

• Acetoacetic Acid Sodium Salt: Evidence Guide

  2026-10-06

  Acetoacetic acid sodium salt, also called sodium 3-oxobutanoate, is a sodium-form ketone body metabolite used to frame questions in energy metabolism research. Vendor specifications establish chemical identity and handling information, while peer-reviewed ketone-body literature supports biological relevance but does not establish clinical efficacy for the product.

• Malate, Metabolic Flux, and Translational Immunology

  2026-10-06

  Malate is more than a TCA-cycle metabolite: it is a context-sensitive lens on mitochondrial redox, metabolic flux, and tumor–immune communication. This thought-leadership analysis connects malate biology with recent findings on PDHA1 succinylation and macrophage immune escape in cholangiocarcinoma while defining the evidence boundaries for translational research.

• Canagliflozin: Reading a Negative mTOR Result

  2026-10-05

  Canagliflozin hemihydrate is best understood through the distinction between SGLT2 biology and mTOR pathway screening. This article interprets a recent drug-sensitized yeast study, explains what its negative result does—and does not—demonstrate, and outlines evidence-aware applications in metabolic research.

8615 records 1/575 page Next 12345 下5页 Last page